InnovaDerma PLC Form 8 (OPD) - InnovaDerma plc (3181I)
April 13 2022 - 11:30AM
UK Regulatory
TIDMIDP
RNS Number : 3181I
InnovaDerma PLC
13 April 2022
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
With reference to the Form 8 released by Innovaderma plc (RNS
number 8454H) on 8 April 2022 at 15:00, this was released without
information relating to warrants held in respect of Ordinary Shares
by a Connected Adviser. Investors should refer to this Form 8
announcement.
1. KEY INFORMATION
(a) Full name of discloser: InnovaDerma plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): N/A
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s),
settlor and beneficiaries must be named.
----------------
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: InnovaDerma plc
Use a separate form for each offeror/offeree
----------------
(d) Is the discloser the offeror or the offeree? Offeree
----------------
(e) Date position held: 08 April 2022
The latest practicable date prior to the disclosure
----------------
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect No
of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
----------------
2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates
Class of relevant security: EUR 0.1 Ordinary
Interests Short positions
------------ ------------------
Number % Number %
-------- ------------- ---
(1) Relevant securities owned and/or controlled: Nil - Nil -
-------- ------------- ---
(2) Cash-settled derivatives: Nil - Nil -
-------- ------------- ---
(3) Stock-settled derivatives (including options) and agreements to purchase/sell: Nil - Nil -
-------- ------------- ---
Nil - Nil -
TOTAL:
-------- ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities
Class of relevant security in relation to which subscription right exists: Nil
Details, including nature of the rights concerned and relevant percentages: Nil
----
3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE
Details of any interests, short positions and rights to subscribe (including directors' and
other employee options) of any person acting in concert with the party to the offer making
the disclosure:
(A) Ordinary Shares of EUR0.10 each ("Ordinary Shares") held by directors of Innovaderma Plc
and their close relatives and related trusts (excluding the options and awards set out below):
Name Number of Ordinary % of Ordinary
Shares held Shares held
Ross Andrews (Director) 322,290 1.14
------------------- --------------
Blake Hughes (Director) 128,571 0.45
------------------- --------------
Simon Pyper (Non-Executive
Director) 71,428 0.25
------------------- --------------
Andrew Dunderdale (Director) 24,937 0.08
------------------- --------------
Mark Ward (Non-Executive
Director) 5,049,076 17.99
------------------- --------------
(B) Options held by directors of Innovaderma plc in Innovaderma plc shares
Granted Total Exercise Vest Date Expiry Date
number Price
of Ordinary
Shares
Ross Andrews 22 January 75,000 GBP1.20 22/01/2023 22/01/2030
2020
------------ ------------- --------- ----------- ------------
Andrew 31 December 95,500 GBP0.35 31/12/24 31/12/31
Dunderdale 2021
------------ ------------- --------- ----------- ------------
Blake Hughes 31 December 125,000 GBP0.35 31/12/24 31/12/31
2021
------------ ------------- --------- ----------- ------------
(C) Warrants in respect of Ordinary Shares by a Connected Adviser
Name Conversion Number of
Price warrants held
finnCap Ltd 35 pence 214,285
----------- ---------------
Note: the 214,285 warrants held by finnCap have a grant date of 09/04/21 and an expiry date
of 30/04/23.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the party to the offer making the disclosure or any person acting
in concert with it:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the party
to the offer making the disclosure, or any person acting in concert with it, and any other
person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
Supplemental Form 8 (SBL) NO
---
Date of disclosure: 13 April 2022
Contact name: Ross Andrews, Chairman
-----------------------
Telephone number: +44 (0) 7973839767
-----------------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service.
The Panel's Market Surveillance Unit is available for
consultation in relation to the Code's disclosure requirements on
+44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk .
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FEEEXLFFLZLFBBQ
(END) Dow Jones Newswires
April 13, 2022 11:30 ET (15:30 GMT)
Innovaderma (LSE:IDP)
Historical Stock Chart
From May 2024 to May 2024
Innovaderma (LSE:IDP)
Historical Stock Chart
From May 2023 to May 2024